M-A de estudos randomizados | Risco de eventos adversos cutâneos em pacientes oncológicos tratados com inibidores da fosfatidilinositol-3-quinase. 29 Ago, 2022 | 16:35h Risk of cutaneous adverse events in cancer patients treated with phosphatidylinositol-3-kinase inhibitors: A systematic review and meta-analysis of randomized controlled trials – Cancer Medicine